Lina Le
Lina Le
Lina Le is a Research Assistant in the Functional Phosphoproteomics group. She completed her Master of Biomedical Science at the University of Melbourne.
Her master's research investigated how the cancer therapies, Ibrutinib and Venetoclax, influence the immune system over time in patients with Marginal Zone Lymphoma. The study was conducted at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital under the supervision of Professor David Ritchie, Associate Professor Rachel Koldej, and Dr Joanne Davis.
Lina also contributed as an Executive Committee Member for the Students of the Royal Melbourne (StoRM) Society.
Her master's research investigated how the cancer therapies, Ibrutinib and Venetoclax, influence the immune system over time in patients with Marginal Zone Lymphoma. The study was conducted at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital under the supervision of Professor David Ritchie, Associate Professor Rachel Koldej, and Dr Joanne Davis.
Lina also contributed as an Executive Committee Member for the Students of the Royal Melbourne (StoRM) Society.
Lina Le is a Research Assistant in the Functional Phosphoproteomics group. She completed her Master of Biomedical Science at the University of Melbourne.
Her master's research investigated how the cancer therapies, Ibrutinib and Venetoclax,...
Her master's research investigated how the cancer therapies, Ibrutinib and Venetoclax,...
Lina Le is a Research Assistant in the Functional Phosphoproteomics group. She completed her Master of Biomedical Science at the University of Melbourne.
Her master's research investigated how the cancer therapies, Ibrutinib and Venetoclax, influence the immune system over time in patients with Marginal Zone Lymphoma. The study was conducted at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital under the supervision of Professor David Ritchie, Associate Professor Rachel Koldej, and Dr Joanne Davis.
Lina also contributed as an Executive Committee Member for the Students of the Royal Melbourne (StoRM) Society.
Her master's research investigated how the cancer therapies, Ibrutinib and Venetoclax, influence the immune system over time in patients with Marginal Zone Lymphoma. The study was conducted at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital under the supervision of Professor David Ritchie, Associate Professor Rachel Koldej, and Dr Joanne Davis.
Lina also contributed as an Executive Committee Member for the Students of the Royal Melbourne (StoRM) Society.
Top Publications
- Davis, JE, Le, LH, Ludford-Menting, M, Holzwart, N, Handunnetti, SM, Tam, CS, Anderson, MA, Ritchie, DS, Koldej, R. Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment. Blood 144(Supplement 1) : 4384 -4384 2024 view publication
- Palmer, AS, Alldritt, I, Apro, W, Huckstep, H, Horwath, O, Le, L, Cree, T, Deemer, S, Watson, E, Mills, R, et al. Ageing blunts the phospho-proteomic response to resistance exercise in humans. 2026 view publication
Career information
Share //
